(IN BRIEF) H.U. Group Holdings Inc. and Fujirebio have announced the launch of Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These assays can quantitatively measure Neurofilament light (NfL) … Read the full press release
Posted in Belgium, Education, Healthcare, Management, News, Science, Technology
Tagged Alzheimer’s disease, Belgium, Christiaan De Wilde, CLEIA, Fujirebio, H.U. Group Holdings, human cerebrospinal fluid (CSF), LUMIPULSE G immunoassay systems, Lumipulse G NfL Blood assays, Lumipulse G NfL CSF, multiple sclerosis, Neurofilament light (NfL), Parkinson disease, plasma/serum, Quantitative NfL Assays, Research Use Only
IVD-seq project received 720K EURO research grant from Flanders Innovation & Entrepreneurship (VLAIO) (PRESS RELEASE) GENT, 8-Dec-2020 — /EuropaWire/ — Fujirebio Europe announces that together with its partner OHMX.bio, a provider of cutting-edge “omics” solutions, have been awarded a 720K … Read the full press release
Posted in Belgium, Financial, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Christiaan De Wilde, clinical in vitro diagnostics, clinical IVD expertise, diagnostics.”, Flanders Innovation & Entrepreneurship, Fujirebio Europe, genetic sequencing, genotyping, IVD, IVD modular solution, IVD solution, IVD-seq, IVD-seq project, Next generation sequencing, NGS, OHMX.bio, omics solutions, Prof. Gerben Menschaert, research grant, TGS, TGS IVD platform, third generation sequencing, VLAIO
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
